Feature | Antiplatelet and Anticoagulation Therapies | June 10, 2015

PEGASUS TIMI-54 Study Shows Brilinta Reduces Thrombotic Events Following Heart Attack

Oral antiplatelet significantly reduces risk of myocardial infarction, stroke and death

Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results

June 9, 2015 - AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose aspirin, at the American College of Cardiology (ACC) 64 th annual scientific session and expo in March. The study compared Brilinta to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrolment. Study results were simultaneously published in the New England Journal of Medicine online.

Key findings included:

  • Both 90mg and 60mg study doses of ticagrelor with aspirin significantly reduced the primary composite endpoint of cardiovascular (CV) death, myocardial infarction (MI) or stroke compared to placebo; and
  • As expected with an oral antiplatelet and consistent with studies in similar patient populations, TIMI Major Bleeding, the study's primary safety endpoint, was higher with both doses of ticagrelor plus aspirin compared to placebo plus aspirin. Importantly, the rates of intracranial haemorrhage (bleeding within the skull) and fatal bleeding were low and were similar between study groups and the placebo arm.

 

Recent research has shown that one in five patients will have a further heart attack, stroke or CV death in the subsequent three years following a heart attack, even if patients were event free after 12 months. For patients more than one year on from a heart attack, the current standard of care is aspirin alone. The PEGASUS-TIMI 54 study was designed to investigate the effect of adding ticagrelor at 60mg and 90mg to low dose aspirin on reducing the risk of CV death, heart attack or stroke in patients aged 50 and older with a history of heart attack and one additional CV risk factor.

In this trial, both study doses of ticagrelor significantly reduced the primary endpoint of CV death, MI or stroke compared to placebo. The rates at three years were 7.85 percent in the ticagrelor 90mg arm, 7.77 percent in the ticagrelor 60mg arm, and 9.04 percent in the placebo arm (Hazard Ratio (HR) for ticagrelor 90mg vs placebo 0.85, 95 percent CI 0.75 – 0.96, P=0.0080; HR for ticagrelor 60mg vs placebo 0.84, 95 percent CI 0.74 – 0.95, P=0.0043).

The effect of ticagrelor on each of the components of the primary endpoint was consistent. A numerical decrease in the secondary endpoints of cardiovascular death and all-cause mortality was observed, but did not reach statistical significance.

In addition, the primary efficacy endpoint of both doses of ticagrelor appeared consistent across major subgroups including age, sex, index MI type (STEMI/NSTEMI), time from qualifying MI, diabetes, aspirin dose, history of percutaneous intervention (angioplasty) and geographical region.

As expected, TIMI Major bleeding was higher with both doses of ticagrelor compared to placebo, with rates at three years of 2.60 percent in the ticagrelor 90mg arm, 2.30 percent in the ticagrelor 60mg arm, and 1.06 percent in the placebo arm (HR for ticagrelor 90mg vs placebo 2.69, 95 percent CI 1.96 – 3.70, p<0.001; HR for ticagrelor 60mg vs placebo 2.32, 95 percent CI 1.68 – 3.21, p<0.001).

However, the rates of fatal bleeding or intracranial haemorrhage were low and similar between treatment arms.

Fatal bleeding rates at three years were 0.11 percent in the ticagrelor 90mg arm, 0.25 percent in the ticagrelor 60mg arm, and 0.26 percent in the placebo arm (HR for ticagrelor 90mg vs placebo 0.58, 95 percent CI 0.22 – 1.54, p=0.27; HR for ticagrelor 60mg vs placebo 1.00, 95 percent CI 0.44 – 2.27, p=1.00).

Intracranial hemorrhage rates at three years were 0.56 percent in the ticagrelor 90mg arm, 0.61 percent in the ticagrelor 60mg arm, and 0.47 percent in the placebo arm (HR for ticagrelor 90mg vs placebo 1.44, 95 percent CI 0.83 – 2.49, p=0.19; HR for ticagrelor 60mg vs placebo 1.33, 95 percent CI 0.77 – 2.31, p=0.31).

The PEGASUS-TIMI 54 study, part of the PARTHENON program, involved more than 21,000 patients from over 1,100 sites in 31 countries.

For more information: www.astrazeneca.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init